The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

ABSTRACT:

Objectives

To assess the safety of intravitreal bevacizumab (IVB) as a monotherapy and to evaluate the relationship between quality of treatment and adverse events.

Data sources

Cochrane Library, Ovid MEDLINE, MEDLINE in-process, Ovid EMBASE and Toxicology Literature Online (TOXLINE) from January 2009 to May 2012. Studies included in an earlier systematic review were also assessed for inclusion.

Study eligibility criteria, participants and interventions

Randomised controlled trials (RCTs), controlled trials or observational studies including ≥10 participants reporting adverse events data following IVB monotherapy as a primary treatment in patients (aged 18 years or more) with any eye condition were included.

Study appraisal and synthesis methods

Study selection

SUBMITTER: Poku E 

PROVIDER: S-EPMC4120420 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature